Log in  First Connection?

VaccinesArchives

Willingness and understanding of the safety and effectiveness of COVID‐19 vaccines in young children: a cross‐sectional study among parents in Malaysia
Vaccines
 6 min.

 Published on 22/02/2024 |  Original article (Full-text)  | Norkasihan Ibrahim PhD et al. | Journal of Pharmacy Practice and Research 2024; AOP: 10.1002/jppr.1901

The common clinical features of coronavirus disease 2019 (COVID‐19) in children include fever, cough, rhinorrhoea, and diarrhoea. A meta‐analysis examining complications in young patients demonstrated multisystem inflammatory syndrome and neurological involvement as the most prevalent sequelae....

Advertisement
Advertisement

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies
Vaccines
 8 min.

 Published on 15/02/2024 |  Original article (Full-text)  | Wynne Chris et al. | Infectious diseases and therapy 2024; 13(1): 57-78

During the global pandemic, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in considerable illness and death. By the end of May 2023, more than 760 million confirmed cases of COVID-19 and more than 6.9 million deaths had...

Can adverse cardiac events of the COVID-19 vaccine exacerbate preexisting diseases?
Vaccines
 0 min.

 Published on 08/02/2024 |  Original article (Full-text)  | Mohammed S. Razzaque et al. | Expert Review of Anti-infective Therapy 2024; OnlineFirst(-): 1-7

SARS-CoV-2 infection and COVID-19 vaccination can both lead to serious cardiac conditions such as myocarditis, arrhythmia, acute myocardial infarction, and coagulopathy. Further studies are needed to better understand the risks and benefits of COVID-19 vaccination, and to determine the best course of...

One dose versus two doses of COVID‐19 vaccine for the prevention of breakthrough infections among people previously infected with SARS‐Cov‐2
Vaccines
 2 min.

 Published on 01/02/2024 |  Original article (Full-text)  | Fangjian Guo et al. | Journal of Medical Virology 2024; 96(1): 29391

The emergence of COVID‐19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), triggered an urgent global effort to develop effective vaccines. COVID‐19 vaccines (especially mRNA vaccines) have been shown to be effective in preventing severe acute respiratory...

Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data
Vaccines
 5 min.

 Published on 25/01/2024 |  Original article (Full-text)  | Wei Qin et al. | Journal of Viral Hepatitis 2024; 31(3): 143-50

Hepatitis B vaccine (HepB) immunization is the most cost‐effective and efficient intervention for preventing hepatitis B virus (HBV) infection and HBV‐associated diseases worldwide. A primary three‐dose series of HepB induces protective antibody concentrations in over 95% of healthy...